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Previous studies demonstrate that the protein of neuropeptide Y (NPY) is abnormal
in depression patients, but the changes of NPY in different types of depression
are unclear. This study was aimed to examine protein and mRNA expression levels
of NPY in 159 cases with four groups including post-stroke depression (PSD)
group, stroke without depression (Non-PSD) group, major depressive disorder (MDD)
group and normal control (NC) group. The protein and gene expression analysis
were performed by enzyme-linked immunosorbent assay (ELISA) and quantitative
polymerase chain reaction-based methods. One way analysis of variance (ANOVA),
chi-square tests and nonparametric test were used to evaluate general characteristics,
clinical and biological materials. In order to explore the role of NPY in different
types of depression, the partial correlations, binary logistic regression analysis and
receiver operating characteristic (ROC) curve were calculated for PSD and MDD
groups. There are significant differences of NPY protein (Fdf(3) = 5.167, P = 0.002)
and mRNA expression levels ( 2χ <Kruskal−Wallis, df(3) = 20.541, P 0.001) among
four groups. Bonferroni multiple comparisons found that the NPY protein was
significantly decreased in PSD (FBonferroni = −7.133, P = 0.002) and Non-PSD group
(FBonferroni = −5.612, P = 0.018) compared with NC group. However, contrasted
with MDD group, the mRNA expression was increased in PSD and Non-PSD
group by nonparametric test (all P < 0.05). In binary logistic analyses, NPY
mRNA expression was independent predictors of PSD (odds ratio: 1.452, 95%
CI, 1.081–1.951, P = 0.013). The ROC curve showed NPY mRNA had a general
prognostic accuracy (area under the curve: 0.766, 95% CI, 0.656–0.876, P < 0.001).
This is the first study to explore the distinguishing function of NPY in different
types of depression. It will provide help in the identification of different subtypes of
depression.
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INTRODUCTION
Depression is one of the most frequently encountered forms of
mental illness and more than 350 million people battle with
it every day (Smith, 2014). Post-stroke depression (PSD) as a
subtype of depression is a frequent complication after stroke, it is
related to a variety of adverse health outcome including increased
disability, difficult to recover and risk of suicide (Paolucci et al.,
2001; Pompili et al., 2012). According to a meta-analysis, the
prevalence of depression was 33% among stroke survivors by
pooled estimate (Hackett et al., 2005).
Despite the high morbidity of PSD and major depressive
disorder (MDD), there is yet little insight into the underlying
neurobiological mechanisms. Preclinical and clinical studies
suggest that many mechanisms are involved in this disorder
including neurotrophic signaling, cellular plasticity and
activation of the hypothalamic-pituitary-adrenal (HPA) axis
(Spalletta et al., 2006; Loubinoux et al., 2012). In the aspect
of the neurotrophic and neurochemical factors, brain-derived
neurotrophic factor, glial cell line-derived neurotrophic factor
and vascular endothelial growth factor were proved to play
an important role in the pathophysiology of depression
and antidepressant action of therapeutic interventions
(Sharma et al., 2016). In addition, Neuropeptide Y (NPY),
a 36-amino acid peptide, is widely distributed in the central
and peripheral nervous systems such as most cortical areas,
hippocampus, amygdala, olfactory bulb and spinal cord of
the rat and human brain (Dumont et al., 1992). These brain
regions are closely related to stress responses and mood
disorders. With this in mind, researchers suggested that it
as neuromodulators associated with MDD (Morales-Medina
et al., 2010). NPY plays a regulatory role in feeding, body
weight, sleep, cognition and emotion (Gehlert, 2004). In
addition, NPY was found to regulate neurogenesis in the
hippocampus. Significantly decreased NPY in the dorsal
hippocampus was found in the maternally separated rats and
Flinders sensitive line (FSL) rats (a genetic-based model of
depression-like behavior; Caberlotto et al., 1999; Jiménez-
Vasquez et al., 2001). Moreover, human and postmortem
studies found decreased NPY levels in cerebrospinal fluid
(CSF), plasma the frontal cortex and the caudate nucleus of
depressive or attempted suicide patients, especially in repeatedly
attempted suicides (Widerlöv et al., 1988; Widdowson et al.,
1992; Westrin et al., 1999; Heilig, 2004). However, the NPY
mRNA which was region specific in depressive-like animal
models, significantly decreased in the nucleus accumbens,
medial amygdala, hippocampal dentate gyrus, CA regions
and prefrontal cortex, but increased in the arcuate nucleus
and anterior cingulate cortex in the FSL and chronic mild
stressed rats (Caberlotto et al., 1998; Sergeyev et al., 2005;
Bjørnebekk et al., 2006; Zambello et al., 2008; Melas et al.,
2012).
Withal NPY mediates neuroprotection against focal ischemia
and regulates cerebral blood flow (Lundberg et al., 1982;
Tuor et al., 1990; Cheung and Cechetto, 2000). Previous
studies showed that NPY protein levels were increased in
cortical and subcortical tissues around the lesions in the
ischemic and hemorrhagic animal models (Kharlamov et al.,
2007; Montaner et al., 2012). In plasma, NPY levels were
significantly lower compared to the control group in the
acute phase of female stroke patients (Baranowska et al.,
2013).
Clinical and experimental investigations support that NPY
is involved in the pathophysiology of depression and stroke.
What is more, PSD as a disease integrated above two reciprocally
relational factors, so we speculate NPY could be a molecular
joint in this disease. Therefore, the first aim of this study was
to explore the changes of NPY protein content and mRNA
expression in PSD, stroke without depression (Non-PSD) and
MDD patients. Then we further analyze the difference of
NPY between the subtypes of depression including PSD and
MDD patients.
MATERIALS AND METHODS
Study Population
This study was approved by the Medical Ethics Committee for
Clinical Research of Zhongda Hospital Affiliated to Southeast
University. One-hundred and fifty-nine subjects including PSD
(n = 39), Non-PSD (n = 42), MDD (n = 40) patients and
normal control (NC; n = 38) were recruited during the
period from July 2013 to December 2014 and they all gave
written informed consent. Stroke patients were verified from
computed tomography or magnetic resonance imaging reports
within 7 days. MDD patients were carefully screened with
the Structured Clinical Interview for the Diagnostic Statistical
Manual of Mental Disorder (DSM-IV; SCID) by psychiatrists
treating two participants PSD patients fulfilled the following
diagnostic criteria: (1) had stroke before, or stroke occurs earlier
than depressive symptoms; (2) had three or more depressive
symptoms in nine symptoms of MDD in DSM-IV, at least one of
the symptoms (1. depressed mood, 2. loss of interest or pleasure)
is present; (3) the symptoms cause clinically significant distress
or impairment in social, occupational or other important areas of
functioning; (4) depressive symptoms lasting more than 1 week;
and (5) free of other major psychiatric disorders, including
schizophrenia, bipolar disorder, substance abuse (caffeine,
nicotine and alcohol; Yue et al., 2015). Moreover, the patients
are all antidepressants-naïve. The severity of depression and
cognitive function were evaluated by Hamilton depression rating
scale (HDRS-17) and mini-mental state examination (MMSE).
HDRS was the most promising evaluation scale for PSD patients
evidenced by a meta-analysis (Meader et al., 2014). MMSE as a
global measurement of cognitive functioning was administered
(Folstein et al., 1975).
Blood Collection
Venous blood samples were collected via venipuncture in
EDTA-anticoagulant and coagulant tubes after the admission.
Whole blood was directly stored at −80◦C for further study.
Samples in coagulant tubes were separated by centrifugation
(3000 rcf for 30 min at 4◦C). The separated serum was stored at
−80◦C until the assay was performed.
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Determination of Serum Protein Level
Using Enzyme-Linked Immunosorbent
Assay (ELISA)
NPY levels were measured in duplicate using enzyme-
linked immunosorbent assay (ELISA) method (Human NPY
Quantikine kit, EMDMillipore Corporation, USA) following the
manufacturer’s instructions. NPY content was expressed as pg of
protein/ml of serum, with a detection limit sensitivity of 2 pg/ml.
The Expression of NPY mRNA
RNA Extraction and Reverse Transcription
Total RNA was extracted from the peripheral blood lymphocytes
using QIAamp RNA Blood Mini Kit (Qiagen, Hilden, Germany)
following the manufacturer’s protocol. One microgram of total
RNA got through the last process was reverse transcribed into
cDNA using random hexanucleotide primers and Sensiscript
Reverse Transcription Kit (Qiagen, Hilden, Germany) according
to the instruction manual. Obtained cDNA was used in the
quantitative polymerase chain reaction (qPCR).
Detection of Gene Expression Using qPCR Method
qPCR based on TaqMan technology was performed to test the
NPY mRNA expression. Probe primers were designed using the
Primer Express Software v2.0 by ABI company. β-actin (ACTB)
was used as reference transcript and their primer sequences were
listed in Table 1.
qPCR was carried out in a final volume of 16 µl, with
1 µl cDNA, 8 µl 2× SYBGEEN PCR mix, 1 µl of each
primer and 5 µl H2O. Amplification was performed for
2 min at 95◦C to activate FastStart Taq DNA polymerase
and 40 rounds of 10 s at 94◦C, 10 s at 59◦C and 40 s
at 72◦C for amplification and signal analysis. ABI ViiA 7
Real-Time PCR System from Applied Biosystems was used to
detect amplifications. Each sample was assayed in triplicate in
independent reactions. Real-time PCR data were automatically
calculated by the data analysis module. Relative expression
changes were calculated with the 2−44 method using ACTB as
the reference transcript.
Statistical Analysis
Demographic and clinical characteristics were described in
quantitative terms of mean (M) and standard deviation (SD).
Chi-square (χ2) test and one-way analysis of variance (ANOVA)
TABLE 1 | The primers for qPCR.
Gene name Primer Sequence
NPY NPY-taqman-F 5′-CGGAGGACATGGCCAGATAC-3′
NPY-taqman-R 5′-GCCTGGTGATGAGGTTGATGTA-3′
NPY-taqman ACTCGGCGCTGCGA
ACTB ACTB-F 5′-AGGCACCAGGGCGTGATG-3′
ACTB-R 5′-CGCCCACATAGGAATCCTTCT-3′
ACTB-Taqman TGGGCATGGGT
Note: qPCR, quantitative polymerase chain reaction; NPY, neuropeptide Y;
ACTB, beta-actin.
were used to evaluate general characteristics. The HDRS and
NYP protein were calculated by analysis of covariance (age
and gender as covariates). The nonparametric test (Kruskal-
Wallis H test) was used to analyze the mRNA level of
NPY. The abnormal data determined by M ± 3 SD were
excluded.
Then the following statistical analyses were calculated in
the PSD and MDD groups. The partial correlation was used
to evaluate bivariate correlations with age and gender as
covariates. The influence of NPY in different types of depression
was assessed by binary logistic regression analysis and the
results were expressed as adjusted odds ratios (OR) with the
corresponding 95% confidence interval (CI). Finally, receiver
operating characteristic (ROC) curve was utilized to evaluate the
accuracy of NPY to predict the PSD.
All analyses were conducted using SPSS Version
20.0 statistical software (SPSS Inc. Chicago, IL, USA).
RESULTS
Demographic and Neuropsychological
Results
The demographic and neuropsychological information for all
participants are listed in Table 2. The age, gender, HDRS-17
and MMSE have significant differences (all P < 0.05) among
four groups except the education level (mean square = 19.746,
Fdf(3) = 1.218, P = 0.305).
The NPY Protein and mRNA Expression
Level
In the protein level, analysis of covariance showed that there is a
statistical difference among four groups (mean square = 357.279,
Fdf(3) = 5.167, P = 0.002), with two patients in PSD group,
eliminated on account of being below the sensitivity. Compared
with NC group, a significantly decreased content in PSD
(FBonferroni =−7.133, standard error (SE) = 1.920, P = 0.002) and
Non-PSD group (FBonferroni =−5.612, SE = 1.862, P = 0.018) was
discovered by Bonferroni multiple comparisons (see Table 2).
In the mRNA expression aspect, the statistically
significant difference was also found among four groups
(χ2Kruskal−Wallis, df(3) = 20.541, P < 0.001), however, multiple
comparison tests showed that both the PSD and Non-PSD
groups have significantly increased expression compared to
MDD group (0.92 ± 1.27 in PSD vs. 0.11 ± 0.16 in MDD,
0.34 ± 0.34 in Non-PSD vs. 0.11 ± 0.16 in MDD, all P < 0.05,
see Table 2).
The Predictive Effect of NPY on PSD and
MDD
No relationship between the NPY and neuropsychological scales
including HDRS-17 and MMSE was found in this study.
In logistic analysis, serum NPY concentration and mRNA
expression were independent predictors of PSD with OR of 0.933
(95% CI, 0.871–1.000; P = 0.050), 1.452 (95% CI, 1.081–1.951;
P = 0.013), respectively (seeTable 3). As showed in Figure 1, NPY
mRNA had a higher prognostic accuracy (area under the curve
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TABLE 2 | The demographic and clinical data among four groups.
Item PSD group Non-PSD group MDD group NC group F/χ2 P value
(n = 39) (n = 42) (n = 40) (n = 38)
Age (years) 62.44 ± 10.34 61.10 ± 6.58 58.70 ± 9.92 57.58 ± 5.28 2.761 0.044a
Gender (male/female) 20/19 25/17 9/31 22/16 14.316 0.003b
Education level (years) 8.15 ± 4.36 9.43 ± 4.01 9.40 ± 4.77 8.24 ± 2.56 1.218 0.305a
HDRS 16.00 ± 5.45 3.36 ± 2.02 19.45 ± 4.75 2.18 ± 1.98 203.32 <0.001c
MMSE 22.64 ± 6.80 27.00 ± 2.45 27.08 ± 1.45 28.47 ± 1.45 28.46 <0.001c
NPY (pg/ml)† 17.65 ± 8.41# 19.17 ± 8.69# 20.50 ± 8.19 24.79 ± 7.93 5.167 0.002a
NPY mRNA 0.92 ± 1.27∗ 0.34 ± 0.34∗ 0.11 ± 0.16 1.00 ± 1.95 20.541 <0.001d
(2−11Ct)‡
Note: aone-way ANOVA. bChi-square test. cAnalysis of covariance, age, gender as covariates. dKruskal-Wallis H test. #P < 0.05 compared with NC group.
∗P < 0.05 compared with MDD group. PSD, post-stroke depression; Non-PSD, stroke without depression; MDD, major depressive disorder; NC, normal control; HDRS,
Hamilton depression rating scale, MMSE, Mini-mental state examination. †Two abnormal data were excluded (two below the sensitive value in PSD group); ‡Fifteen
abnormal data were excluded (three PSD patients, seven Non-PSD patients, two MDD patients and three NC subjects).
TABLE 3 | The results of the logistic regression model in post-stroke depression (PSD) and major depressive disorder (MDD) groups.
β value Standard error Warld χ2 (df = 1) P value OR 95% CI
NPY protein (pg/ml) −0.069 0.035 3.858 0.050 0.933 0.871–1.000
NPY-mRNA expression 0.373 0.151 6.137 0.013 1.452 1.081–1.951
Note: The forward logistic regression analysis was used to determine the predictive value of NPY. NPY, neuropeptide Y; OR, odds ratios; CI, confidence intervals; Statistical
significance was set at P < 0.05.
(AUC), 0.766 (95% CI, 0.656–0.876), P < 0.001) as compared
to serum concentration (AUC, 0.407 (95% CI, 0.275–0.540),
P = 0.176).
DISCUSSION
The present study provides evidence that the protein and
transcriptional changes of NPY occur in PSD and different
FIGURE 1 | Receiver operating characteristic (ROC) curve for mRNA
expression and serum concentration of neuropeptide Y (NPY) which
areas under the line were 0.766 (95% CI, 0.656–0.876, P < 0.001, solid
black line) and 0.407 (95% CI, 0.275–0.540, P = 0.176, dotted black
line), respectively.
depressions. The protein content shows a consistent decline in
PSD, Non-PSD and MDD group, but only PSD and Non-PSD
groups reach statistical significance when compared with NC
group. While the transcriptional levels display significant
differences between PSD, Non-PSD and MDD group. Moreover,
the NPY mRNA expression can identify the different types of
depression to some extent. It’s important to note that this is an
exploratory study with small sample size, so replication of these
findings in larger cohorts will be necessary for validation.
The reduced protein and mRNA of NPY in MDD group were
obtained in genetic rat models of depression and other clinical
research, suggesting that these changes most likely are triggered
by stress (Lachman et al., 1992; Westrin et al., 1999; Melas
et al., 2013). Previous studies demonstrated that enhancing NPY
function boosts resilience (Christiansen et al., 2011; Southwick
and Charney, 2012; Cohen et al., 2015). NPY can be served as a
potential anti-depressive factor and used to monitor treatment
of depression by recent findings (Bigio et al., 2016; Nakhate
et al., 2016; Ozsoy et al., 2016; Wagner et al., 2016). NPY is one
of the most abundant peptides in the central nervous system
and mediates mood disorder, stress response and antidepressant
effect mainly through the Y1 and Y2 receptors, which are densely
expressed in the cortex, hippocampus and amygdala (Dumont
et al., 1998; Price and Drevets, 2012). So it may be speculated
that NPY participates in MDD through modulating the internal
andmutual function of these brain regions. Furthermore, Mickey
et al. (2011) found that individuals with low-expression NPY
genotypes were inclined to negative affective experience under
stress. Taken together, the evidence suggested that low NPY
increased the risk for depression through adding sensitivity to
negative stimuli and declining brain reserve capacity at the
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cellular levels and also possibly at the neural circuit levels (Freret
et al., 2015).
Compared with the NC group, the change of protein
had a significant difference in PSD and Non-PSD patients.
The possible explanation could be that stress was the cause
for stroke and depression (Sergeyev et al., 2005). Another
mechanism could be HPA axis activation, then subsequent
suppression of NPY levels by elevating glucocorticoid (Holsboer,
2000; Makino et al., 2000). Indeed, the neuroprotection
role of NPY suggests that the reduced level counteracts the
positive influence on the central and peripheral systems
in PSD diseases. Other mechanisms including serotonin
receptors and exaggerated inflammatory cytokines initiated
by brain injury and persistent neuronal death might
contribute to PSD (Popa-Wagner et al., 2014; Buga et al.,
2016).
However, the result of mRNA level has a significant difference
between PSD and MDD groups. It was consistent with the
results of ROC and logistic regression analyses, which showed
that NPY mRNA could be conducive to distinguish different
subtypes of depression (PSD and MDD; AUC = 0.766).
These suggest that PSD process the discrepantly pathological
mechanisms though a subtype of depression encompasses many
overlapping syndromes similar to MDD (Alexopoulos, 2003).
The possible explanation was that the gene-expression changes
were effected by the stress property (acute or chronic) as well
as the time accumulation (Conrad and McEwen, 2000; Yang
et al., 2013). MDD patients had decreased NPY protein and
mRNA caused by chronic stress, while PSD patients mixed
acute stress of stroke which leads to a transitory rise of mRNA,
but the protein had no time to be affected for simultaneously
collected blood samples. Moreover, the selected analyte of
NPY mRNA expression, potentially provide new insights into
exploring the molecular mechanism of different subtypes of
depression.
Several issues should be considered in this exploring
study. First, the present study yielded a relatively small
sample size, so the findings cannot be considered categorical.
Second, this was a cross-sectional study and the serum
levels and mRNA of NPY measured at the acute stage
of stroke patients, hence, the long-term dynamic evolution
process of these biological characters is not known. Third,
the NPY might be influenced by other neurochemical or
genetic material, so it is important to enroll a set of subjects
with high homogeneity. Given these limitations, the results
should be considered preliminary and future studies should
be well designed with several time points of large number of
participants.
In conclusion, the present study demonstrates that NPY
is abnormal in stroke, PSD and MDD patients and it has a
significant distinguished function in the different subtypes of
depression. These findings, together with previously published
results, suggest that NPY system provides a novel version for the
mechanism of depression pathology.
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